35 results about "Platelet factor" patented technology

A composition and method for enhancing tissue growth, regeneration, and repair includes a Biological Glue formed by extraction of an Extremely Platelet Rich Plasma (EPRP) derived from whole blood, and subsequent activation and clotting. The Biological Glue may be utilized alone to fill defects or may be used as an adhesive agent for other biological and non-biological materials. These materials may include processed thrombus derived from the activation of EPRP. Additionally, the Extremely Platelet Rich Plasma may be impregnated with directly harvested or cultured cells, including stem cells, or other materials, prior to activation, to form a Biological Implant that may be implanted in vivo. A Platelet Factor Enriched Serum (PFS) derived from the activation of the Extremely Platelet Rich Plasma (EPRP) may be added to the cell cultures in preparation of a Biological Implant, in order to provide additional growth factors that speed the development of the cell cultures.

Methods for determining the presence of heparin / platelet factor 4 antibodies in a sample suspected to contain heparin / platelet factor 4 antibodies are provided, along with apparatus suitable for performing the methods. The method depends upon a color visualization indicating the presence or absence of heparin / platelet factor 4 antibodies in the sample. Preferred methods comprise contacting the sample with particles being complexed to platelet factor 4 (PF4) and which particle-complexed PF4 reacts specifically with heparin / platelet factor 4 antibodies, passing the sample / particle mixture through a filter, and then analyzing the color of the filtrate. The presence of heparin / platelet factor 4 antibodies in the sample is established where the color of the filtrate is substantially different from the color of the receptor-bearing particles.

The invention discloses a preparation method of an autologous platelet-factor-rich plasma (PFRP) preparation. The preparation method is characterized by comprising the steps of: A, preparation of autologous PFRP, to be specific, collecting autologous whole blood, and preparing the autologous PFRP in a centrifuging and freeze-thawing manner; and B, preparation of the PFRP preparation, to be specific, mixing the obtained PFRP with a biological scaffold / autologous somatic cells according to a volume ratio of (3:1)-(1:1) to obtain the PFRP preparation. By means of specially processing the autologous whole blood to obtain the autologous PFRP, pollution risks caused by adding an activating agent are reduced, and the immune risks of a membrane antigen during heterogenous usage are avoided. The autologous PFRP preparation prepared according to the method not only has a good effect of repairing damaged tissues such as meniscus, but also has very good anti-wrinkle, filling and lifting effects.

The invention provides a method for selectively modifying a heparin structure by using biological enzyme, which can improve anticoagulation activity of heparin, reduce combination of heparin with blood protein such as platelet factors and the like, and reduce toxic and side effects. The invention belongs to the field of biological medicine. The antithrombus and anticoagulation activities of the heparin derivatives prepared by the method are 2 to 3 times higher than common heparin medicament, the 2-O-sulfate and 6-O-sulfate contents are about 20 percent of the common heparin, and the combination capability of the heparin derivatives with the platelet factors is about 20 percent of the common heparin. The novel heparin derivatives have high anticoagulation activity and low side effect.

The invention discloses exosome freeze-drying powder, a preparation method of the exosome freeze-drying powder and a preparation comprising the exosome freeze-drying powder. The preparation method of the exosome freeze-drying powder comprises the following steps of: preparing platelet factor-rich plasma: collecting autologous blood for centrifugation, preparing exosome: collecting autologous fat to prepare fat mesenchymal stem cells, and culturing the mesenchymal stem cells, preparing a freeze-drying liquid: mixing the platelet factor-rich plasma and the exosome and adding trehalose for mixing, and performing freeze-drying: performing freeze-drying on the freeze-drying solution. The preparation comprises the exosome freeze-drying powder, hyaluronic acid and saline. The preparation can effectively solve the problems that the existing cosmetic preparation has a poor filling effect, short maintenance time and high immunological rejection response.

Atopic asthma is a chronic, inflammatory lung disease characterized by recurrent breathing problems in response to an allergen. Platelets play an important role in this allergic inflammatory process, by releasing preformed mediators like platelet factor 4 (PF4) and regulated upon activation in normal T cells expressed and secreted (RANTES) upon activation causing eosinophil chemotaxis. The present invention relates to allelic variants of the human Inositol polyphosphate 4-phosphatase (INPP4A) gene and splice variants of the coding sequence, which encodes INPP4A enzyme known to be an important regulator of platelet activation; and provides primers and methods suitable for the detection of these allelic variants for applications such as molecular diagnosis, prediction and prevention of an individual's disease susceptibility, and / or the genetic analysis of the INPP4A gene in a population. The invention also provides an association with the expression profile of INPP4A protein in the mouse model of asthma. Specifically, the invention provides a method for detection of predisposition to atopic disorders / other immunological disorders such as, autoimmune disorders, inflammatory disorders, cancer, multiple sclerosis, fibrosis, tuberculosis, sarcoidosis, hypertension and disorders developing due to hypertension, diabetes and disorders developing due to diabetes, alcohol abuse, anxiety, asthma, chronic obstructive pulmonary disease (COPD), cholecystectomy, degenerative joint disease (DJD), seizure disorder, arthritis, etc. where human Inositol polyphosphate 4-phosphatase (INPP4A) might play an important role due to its involvement in platelet action.

The invention relates to a platelet lysate supported micro-sphere preparation method, and aims to solve the problem of large platelet lysate consumption or poor micro-carrier adsorption effect in existing cell culture. The preparation method includes the steps of platelet lysate preparation, micro-sphere component preparation and platelet factor and micro-capsule supported micro-sphere preparation. A prepared micro-sphere is quite strong in osteoblast carrying capacity, most of cells are fitted on the micro-sphere under the condition that the ratio of osteoblasts to the micro-sphere is 500:1,and only few individual cells are scattered in culture solution. Mesenchymal stem cells on the micro-sphere are good in growth condition, cell viability exceeds 95%, doubling time is short, positive expression rate exceeds 95% in terms of purity, and the preparation method is applied to the technical field of biology.

The invention discloses a bottom-layer blood platelet factor patch and a preparation method of a sPL blood platelet factor gel patch membrane. The bottom-layer blood platelet factor patch and the preparation method of the sPL blood platelet factor gel patch membrane aim at solving the problems that a blood platelet plasmagel product has to be prepared in situ, and a blood platelet factor patch membrane is variable in shape and uneven in thickness and component. The bottom-layer blood platelet factor patch comprises a bottom-layer lining membrane and an upper-layer cover membrane, the middle area of the bottom-layer lining membrane is sunken downward to form a blood platelet factor bearing area, and the blood platelet factor bearing area is coated with collagen and an activating agent; blood platelet factors quickly make contact with the collagen and the activating agent and are quickly and uniformly activated. The bottom-layer blood platelet factor patch and the preparation method of the sPL blood platelet factor gel patch membrane overcome the defects that the conventional blood platelet plasmagel product cannot achieve standardization and cannot be prepared in advance, through a conventional spray coating mode or a conventional mixing mode, the gel patch membrane is not shaped and is uneven in thickness and variable in shape, and gel is crumpled and shrunken. The bottom-layer blood platelet factor patch and the preparation method of the sPL blood platelet factor gel patch membrane are applied to the field of blood platelet factor gel patch membranes.

The invention discloses a preparation method of an allograft-derived platelet-rich gelator. The method comprises the steps as follows: (1) umbilical cord blood collection; (2) primary centrifugation:centrifuging a blood sample at the centrifugation parameter of 1500 r / min for 10 min; sucking a supernatant, a middle layer and the upper end of a red blood cell layer for 0.5-1 mm after centrifugation, and performing secondary centrifugation; (3) secondary centrifugation: performing secondary centrifugation at the centrifugation parameter of 2800 r / min for 10 min; sucking a supernatant liquid after centrifugation until 5 ml of the lower layer is left, which is the platelet-rich factor; and (4) uniformly mixing the platelet-rich factor with a calcium chloride-bovine thrombin solution in the volume ratio being 1:(8-10), leaving the mixture to stand for 2 min or longer to obtain the platelet-rich gelator. The allograft-derived platelet-rich gelator prepared by the method can be used for allograft therapy, has concentration up to 9 times that of original whole blood, can be used for acute and chronic wound repair and can be used as compound artificial bone for treatment of nonunion.

The invention discloses a gene for screening acute myocardial infarction complicated by cardiac rupture and an expression product thereof, which are characterized by application of the platelet factor4(PF4) gene and the expression product thereof to the preparation of an acute myocardial infarction risk prediction marker and a diagnostic preparation. The acute myocardial infarction risk prediction marker and the diagnostic preparation adopt conventional PCR (Polymerase Chain Reaction) relative quantification, a fluorescent quantification kit, protein hybridization, an enzyme-linked immunoassay method and a gene chip to assay the expression level of gene in the peripheral blood of a subject or a patient with acute myocardial infarction. The invention provides the application of the PF4 gene and / or the expression product of the gene as a novel marker for screening acute myocardial infarction complicated by cardiac rupture, provides a novel method for predicting and diagnosing the risk of acute myocardial infarction complicated by cardiac rupture by means of the PF4 gene or the expression product of the gene and utilizes the PF4 gene and the expression product thereof to prepare themarker for predicting the risk of acute myocardial infarction complicated by cardiac rupture and the diagnostic preparation for the first time.

The invention discloses a preparation method and application of conditioned serum rich in cytokines, and the preparation method of the conditioned serum comprises the following steps: taking fresh blood, centrifuging, taking PRP part, freezing, thawing and centrifuging to obtain platelet factor-rich plasma, adding sterile glass beads into the rest part, and carrying out constant-temperature oscillation incubation to obtain the conditioned serum rich in the cytokines. And centrifugally filtering to obtain conditioned serum rich in IL-1Ra, and mixing the platelet factor-rich plasma with the conditioned serum rich in IL-1Ra to obtain conditioned serum rich in cytokines. According to the conditioned serum rich in cytokines prepared by the method, platelet factors and IL-1Ra are fully enriched, the content is greatly increased, and meanwhile, the conditioned serum has the effects of repairing tissue damage, recovering functions and treating tissue inflammation and degeneration, and can be used for treating inflammatory arthritis and other inflammatory diseases caused by factors such as trauma, inflammation, infection and degeneration.

The invention discloses a method for detecting platelet factor-4 without depending on antibody, which belongs to the technical field of biology. The method comprises the following steps: split-charging magnetic beads labeled with -NH2 or -COOH functional groups into a PCR tube, and then placing the PCR tube on a magnetic processor and removing liquid in the tube; taking the PCR tube out, then adding buffer solution into the PCR tube, and mixing the mixture evenly; placing the PCR tube on the magnetic processor and removing the buffer solution in the tube; taking the PCR tube out, adding serum or blood plasma sample into the PCR tube, and mixing the mixture evenly and then standing the mixture; placing the PCR tube on the magnetic processor and removing the liquid in the tube; taking the PCR tube out, adding the buffer solution into the PCR tube, and mixing the mixture evenly; placing the PCR tube on the magnetic processor and removing the buffer solution in the PCR tube; taking the PCR tube out, adding eluent into the PCR tube, and mixing the mixture evenly and then standing the mixture; placing the PCR tube on the magnetic processor and removing the liquid in the tube; and mixing the sucked liquid and saturated sinapic acid solution evenly, sucking the mixed solution to a target of matrix-assisted laser resolution ionization mass spectrometry, and putting the target into a mass spectrometer to detect the target after the solution on the target is crystallized. The method has the advantages of low price and reliable detection result.

The invention relates to the field of adipose-tissue-derived-stromal-cell medical cosmetology, and discloses a separating, culturing and preparation preparing method for adipose tissue-derived stromalcells. According to the method, autologous adipose tissue is treated with the physical method, collagenase does not need to be introduced, long-time tedious treatment does not need, and extracellularmatrixes are reserved and fully used; autologous adipose tissue-derived stromal cells are further amplified through autologous platelet-factor-rich plasma, and sufficient autologous adipose tissue-derived stromal cells and stem cell factors are obtained; the adipose tissue-derived stromal cells and the extracellular matrixes have the good effect on rhytidectomy, soft tissue repairing and facial rejuvenation, and the stem cell factors can be widely applied to skin repairing.

The invention relates to the field of cell medical beauty, and discloses a skin fibroblast precursor cell isolated culture and preparation preparing method. Fibroblast precursor cells are obtained from the autologous skin tissue through a tissue block adherence method. Accordingly, autologous platelet-rich factor plasma is further utilized for expanding the autologous skin fibroblast precursor cells, and the sufficient amount of autologous skin fibroblast precursor cells are obtained. The skin fibroblast cells have the functions of secreting collagen and hyaluronic acid and other extracellularmatrices, and the good effect is achieved for wrinkle removing, soft tissue repairing and facial rejuvenation.

The present invention relates to an activation test for diagnosing heparin-induced thrombocytopenia. More especially, the invention relates to determine functionality and an easy automation test of the heparin-induced thrombocytopenia (HIT). What is measured is the secretion of PF4 (platelet factor 4) from activated thrombocytes.

The invention discloses a preparation method of an autologous platelet-factor-rich plasma (PFRP) preparation. The preparation method is characterized by comprising the steps of: A, preparation of autologous PFRP, to be specific, collecting autologous whole blood, and preparing the autologous PFRP in a centrifuging and freeze-thawing manner; and B, preparation of the PFRP preparation, to be specific, mixing the obtained PFRP with a biological scaffold / autologous somatic cells according to a volume ratio of (3:1)-(1:1) to obtain the PFRP preparation. By means of specially processing the autologous whole blood to obtain the autologous PFRP, pollution risks caused by adding an activating agent are reduced, and the immune risks of a membrane antigen during heterogenous usage are avoided. The autologous PFRP preparation prepared according to the method not only has a good effect of repairing damaged tissues such as meniscus, but also has very good anti-wrinkle, filling and lifting effects.

The invention discloses a filling preparation and a preparation method thereof. The preparation method comprises the following steps that peripheral blood is taken, centrifuging is conducted to obtain platelet-rich plasma, freezing is conducted, then the platelet-rich plasma is taken out and freeze-thawed, centrifuging continues to be conducted to remove membrane fragments at the bottom, and platelet-rich factor plasma is obtained for use; autologous subcutaneous fat is taken, fat granules are obtained and taken, DMSO refrigerating liquid is added in the granules for cryopreservation, then resuscitation is conducted, a sterile saline solution is added in the processed granules, a fat granule suspension is obtained, finally insulin is added in the fat granule suspension, the mixture is shaken evenly for use; the fat granules are centrifuged, upper oil is discarded, fat cells are obtained, and the fat cells are expanded and cultured to the P4 generation, and a fat stem cell resuspension solution is obtained for use; the platelet-rich factor plasma, the fat granule suspension and the fat stem cell resuspension solution are mixed evenly according to a certain volume ratio, and the filling preparation is obtained. According to the filling preparation, the problems that an existing filler material is low in survival rate, short in maintenance time after transplantation and poor in filling effect can effectively solved.

The present invention provides a novel assay for detecting human antibodies specific for a platelet factor 4 (PF4) / heparin complex in a fluid sample. The assay utilizes an immobilized PF4 / polyanion complex and an anti-human antibody conjugated to a non-particulate fluorescent dye to capture and detect human PF4 / heparin antibodies. Various devices, methods and systems based on the disclosed PF4 / heparin assay are also provided.

The invention discloses a preparation method of allogeneic platelet-rich gelatin factor: (1) collection of umbilical cord blood; (2) first centrifugation: centrifuging the blood sample with the centrifugation parameter of 1500r / min for 10 minutes; absorbing the supernatant after centrifugation 0.5-1 mm above the red blood cell layer, the middle layer, and the upper end of the erythrocyte layer, and perform the second centrifugation; (3) The second centrifugation: the centrifugation parameter is 2800r / min, 10min; Platelet-rich factor; (4) Mix platelet-rich factor and calcium chloride-bovine thrombin solution at a volume ratio of 1:8-10, mix well, and let stand for more than 2 minutes to obtain platelet-rich factor gel. The allogeneic platelet-rich gel factor prepared by the method of the present invention can be used for allogeneic treatment, and the concentration can reach 9 times of the original whole blood concentration, can be used for acute and chronic wound repair, and can be used as a composite artificial bone for the treatment of fracture nonunion .

The invention discloses a freeze-dried exosome powder, a preparation method thereof, and a preparation containing the freeze-dried exosome powder. The preparation method of the freeze-dried exosome powder includes the following steps: preparation of platelet-rich factor plasma: taking Autologous blood, prepared by centrifugation, prepared by exosomes; obtained from autologous fat, prepared adipose-derived mesenchymal stem cells, and cultured the mesenchymal stem cells; prepared by lyophilization: platelet-rich factor plasma, and exosomes The body is mixed, and trehalose is added therein, and mixed to obtain the preparation; freeze-drying: the freeze-dried liquid is subjected to freeze-drying to obtain the preparation. The preparation includes freeze-dried exosome powder, hyaluronic acid and physiological saline, which can effectively solve the problems of poor filling effect, short maintenance time and large immune rejection in existing cosmetic preparations.

Methods for determining the presence of heparin / platelet factor 4 antibodies in a sample suspected to contain heparin / platelet factor 4 antibodies are provided, along with apparatus suitable for performing the methods. The method depends upon a color visualization indicating the presence or absence of heparin / platelet factor 4 antibodies in the sample. Preferred methods comprise contacting the sample with particles being complexed to platelet factor 4 (PF4) and which particle-complexed PF4 reacts specifically with heparin / platelet factor 4 antibodies, passing the sample / particle mixture through a filter, and then analyzing the color of the filtrate. The presence of heparin / platelet factor 4 antibodies in the sample is established where the color of the filtrate is substantially different from the color of the receptor-bearing particles.

The invention relates to a neural tube defect prenatal noninvasive diagnosis molecular marker which comprises 6 miRNA (miR-144, miR-142-3p, miR-720, miR-1275, miR-575 and miR-765) and 12 proteins (pro-protein convertase subtilisin / kexin 9, ceruloplasmin, leukaemia inhibitory factor, 14-3-3, paraoxonase, plasma alpha-globulin inhibiting factor H4, serum S protein, glycosyl-phosphatidylinositol specific phospholipase D1, fetuin A, amyloid protein P, plasma alpha-globulin inhibiting factor H2 and platelet factor 4). The invention further provides application of the molecular marker.

The invention discloses an amniotic membrane biological preparation and a preparation method thereof. The amniotic membrane biological preparation adopts the human and animal decellularized amniotic membrane covered with a platelet-rich factor plasma preparation, freeze-dried and irradiated, and stored in low-temperature refrigeration, and is used for repairing clinical skin damage treat. The amniotic membrane biological preparation can significantly improve the healing time of the wound and reduce the scar formation of the wound, and is an industrializable biological preparation with great clinical application prospects.

The invention relates to a matrix in ball form comprising cross-linked fibrinogen, the matrix being free from fibrin, as well as to a method for preparing such a matrix, comprising the following steps: (a) providing an initial composition comprising fibrinogen and a platelet factor; (b) injecting said initial composition into an oil heated to a temperature of 50° C. to 80° C. so as to form an emulsion; (c) mixing the emulsion thus obtained at a temperature of 50° C. to 80° C. until a matrix in ball form is obtained; and (d) isolating the matrix thus obtained. The matrix is used as a cell carrier.

A composition for prolonging skin aging function and improving its preparation method. It relates to a composition and its preparation method. The short-term effect is not obvious and the long-term effect is not long-lasting due to the poor effect of continuous secretion, the poor viscosity of the local simple factor injection, the weak support effect on the base tissue, and the poor ability to balance the cells and tissues. The active ingredients of the composition of the present invention include platelet factor, fibroblast, low molecular weight hyaluronic acid, laminin, superoxide dismutase, sodium gluconate, sodium acetate, sodium chloride, potassium chloride and magnesium chloride. The present invention can prolong the effect of improving skin aging function. Through the application of this combination, the effect of pure platelet factor and pure fibroblast on improving skin aging function can be prolonged.

Provided herein are isolated antibodies or antibody fragments thereof that immunospecifically bind to platelet factor 4 (PF4). In some embodiments the isolated antibodies or antigen-binding fragments thereof comprise a light chain CDR and framework region comprising SEQ ID NO: 4 and a heavy chain CDR and framework region comprising SEQ ID NO: 10. Also provided herein are methods for treating heparin-induced thrombocytopenia (HIT) and methods for reducing the likelihood that subject will become afflicted with HIT. Further disclosed are uses of the isolated antibodies or antibody fragments in the treatment of HIT or the manufacture of compositions for the treatment of HIT.

The invention discloses an ASD (autism spectrum disorders) serum polypeptide marker APOC1-A and an application thereof. An amino acid sequence of the ASD serum polypeptide marker APOC1-A is shown in SEQ.ID.NO.1. A molecule is called as APOC1-A, is a fragment of a platelet factor 4(APOC1) and has an accurate molecular weight being 6,638 Dalton. APOC1-A shows remarkable high expression in serum examination of children suffering from ASD, APOC1-A is detected through an MALDI-TOF-MS (matrix assisted laser desorption ionization / time-of-flight mass spectrometer) or the expression level of APOC1 is detected with an ELISA (enzyme-linked immunosorbent assay) method, and the ASD serum polypeptide marker APOC1-A can be used for detection of ASD serums.

The anti-RSV application of PF4 discloses that the platelet factor 4 can alleviate the symptoms of virus infection by inhibiting the replication of respiratory syncytial virus in the host body, and is an effective anti-respiratory syncytial virus infection intervention measure. The invention provides the use of platelet factor 4 in the preparation of medicines for preventing and / or treating diseases and / or symptoms caused by respiratory syncytial virus infection, and also provides administration routes, dosage forms and medicines suitable for the medicines. Combination with other drugs, etc.; In addition, it also provides a non-therapeutic method for inhibiting respiratory syncytial virus in cells in vitro with platelet factor 4.

The invention relates to the technical field of wet tissues, in particular to a wet tissue with functions of hemostatic and accelerating wound healing and preparation method thereof. According to thewet tissue, plantain and rhododendron are compatible with each other, the number of blood platelet can be effectively increased, the activity of platelet factor can be enhanced, the time for generating thromboplastin is shortened, blood clotting is accelerated, and a function of fast blood stopping is achieved; a lithospermum extracting solution, hazelnut, gulfweed, passionflower, and wheat germ oil are taken as raw materials for preparation of the wet tissue, and are mutually matched with one another, a function of cell activating is achieved, human metabolism is promoted, and wound healing is accelerated; furthermore, winkles generated due to cutis laxa and aging can further be prevented, and functions of skin repairing and skin restoring are achieved; and in addition, sebum secretion can be adjusted, skin is protected, evaporation of moisture from the skin is reduced, and the good moisturizing effect is achieved.